{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:10:58Z","timestamp":1768637458150,"version":"3.49.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","medical.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.mcna.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T19:27:27Z","timestamp":1461353247000},"page":"733-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Movement Disorders"],"prefix":"10.1016","volume":"100","author":[{"given":"Anthony","family":"Julius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelan","family":"Longfellow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2016.03.002_bib1","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.mcna.2016.03.002_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1474-4422(04)00823-3","article-title":"Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease","volume":"3","author":"Clarke","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.002_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0090-9556(25)08003-1","article-title":"A\u00a0comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine","volume":"11","author":"Huebert","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.mcna.2016.03.002_bib7","first-page":"25","article-title":"Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies","volume":"39","author":"Yeh","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib8","first-page":"S1","article-title":"Pharmacokinetics of continuous-release carbidopa\/levodopa","volume":"17","author":"Sage","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mcna.2016.03.002_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","article-title":"Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson's disease","volume":"20","author":"Pahwa","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.mcna.2016.03.002_bib10","first-page":"837","article-title":"Conversion to IPX066 from standard levodopa formulations in advanced Parkinson's disease: experience in clinical trials","volume":"5","author":"Nausieda","year":"2015","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.mcna.2016.03.002_bib11","first-page":"255","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J\u00a0Parkinsons Dis"},{"key":"10.1016\/j.mcna.2016.03.002_bib12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.parkreldis.2014.08.010","article-title":"Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection","volume":"20","author":"Hauser","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1017\/S0317167100041548","article-title":"Sustained release antiparkinson agents: controlled release levodopa","volume":"19","author":"Gauthier","year":"1992","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.mcna.2016.03.002_bib14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archneur.1980.00500520044006","article-title":"Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study","volume":"37","author":"Hoehn","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s007020170056","article-title":"Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat","volume":"108","author":"Jonkers","year":"2001","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.mcna.2016.03.002_bib16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1460-9568.2005.04281.x","article-title":"6-Hydroxydopamine-induced alterations in blood-brain barrier permeability","volume":"22","author":"Carvey","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.mcna.2016.03.002_bib17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/mds.24998","article-title":"Are high doses of carbidopa a concern? A randomized clinical trial in Parkinson\u2019s disease","volume":"27","author":"Brod","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov Disord"},{"issue":"21","key":"10.1016\/j.mcna.2016.03.002_bib19","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1212\/01.wnl.0000312515.52545.51","article-title":"Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain","volume":"70","author":"Marras","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000238401.76928.45","article-title":"Clinical features associated with impulse control disorders in Parkinson disease","volume":"67","author":"Pontone","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcna.2016.03.002_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006564.pub2","article-title":"Dopamine agonist therapy in early Parkinson's disease","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.002_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.mcna.2016.03.002_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40266-013-0090-z","article-title":"Dopamine agonist withdrawal syndrome: implications for patient care","volume":"30","author":"Nirenberg","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.mcna.2016.03.002_bib25","first-page":"7","article-title":"Apomorphine (Apokyn) for advanced Parkinson's Disease","volume":"47","year":"2005","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.mcna.2016.03.002_bib26","series-title":"Apokyn(R) [prescribing information]","year":"2014"},{"key":"10.1016\/j.mcna.2016.03.002_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.mcna.2016.03.002_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1017\/S109285291200003X","article-title":"Practical guide for prescribing MAOIs: debunking myths and removing barriers","volume":"17","author":"Grady","year":"2012","journal-title":"CNS Spectr"},{"key":"10.1016\/j.mcna.2016.03.002_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3949\/ccjm.77a.09103","article-title":"MAO inhibitors: risks, benefits, and lore","volume":"77","author":"Wimbiscus","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.mcna.2016.03.002_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0161-813X(03)00103-7","article-title":"Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation","volume":"25","author":"Youdim","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.mcna.2016.03.002_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients","volume":"329","author":"Ives","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mcna.2016.03.002_bib32","article-title":"Monoamine oxidase B inhibitors for early Parkinson's disease","author":"Turnbull","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.002_bib33","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/WNL.63.7_suppl_2.S7","article-title":"The comparative effects of medical therapies for Parkinson's disease","volume":"63","author":"Horn","year":"2004","journal-title":"Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa0809335","article-title":"A\u00a0double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.002_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S031716710004124X","article-title":"Fluoxetine and selegiline\u2013lack of significant interaction","volume":"21","author":"Waters","year":"1994","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.mcna.2016.03.002_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/106002809402800324","article-title":"Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?","volume":"28","author":"Toyama","year":"1994","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mcna.2016.03.002_bib37","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","article-title":"Serotonin syndrome and the combined use of\u00a0deprenyl and an antidepressant in Parkinson's disease","volume":"48","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(05)79311-9","article-title":"Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease","volume":"351","author":"Nutt","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.002_bib40","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2016.03.002_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","article-title":"Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study","volume":"68","author":"Stocchi","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib42","series-title":"Comtan(R) [prescribing information]","year":"2014"},{"key":"10.1016\/j.mcna.2016.03.002_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/NDT.S5190","article-title":"Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa\/levodopa\/entacapone (Stalevo)","volume":"6","author":"Solla","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.mcna.2016.03.002_bib44","series-title":"Stalevo(R) (carbidopa, levodopa, and entacapone) [prescribing information]","year":"2014"},{"key":"10.1016\/j.mcna.2016.03.002_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and hepatotoxic effects. Tasmar advisory panel","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib46","series-title":"Tasmar(R) [prescribing information]","year":"2013"},{"key":"10.1016\/j.mcna.2016.03.002_bib47","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/mds.5557","article-title":"Amantadine and other antiglutamate agents: management of Parkinson's disease","volume":"17","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(70)90002-4","article-title":"Combined treatment of parkinsonism with L-dopa and amantadine","volume":"2","author":"Godwin-Austen","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.002_bib49","series-title":"Symmetrel(R) (amantadine hydrochloride) [prescribing information]","year":"2009"},{"key":"10.1016\/j.mcna.2016.03.002_bib50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1001\/archneur.1967.00470260014002","article-title":"Cholinergic-anticholinergic antagonism in parkinsonism","volume":"17","author":"Duvoisin","year":"1967","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2016.03.002_bib51","article-title":"Anticholinergics for symptomatic management of Parkinson's disease","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.002_bib52","series-title":"Artane(R) (trihexyphenidyl) [prescribing information]","year":"2003"},{"key":"10.1016\/j.mcna.2016.03.002_bib53","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/01.WNL.0000148479.10865.FE","article-title":"Hallucinations and sleep disorders in PD: six-year prospective longitudinal study","volume":"64","author":"Goetz","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","article-title":"Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms","volume":"27","author":"Lee","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson's disease: a review","volume":"20","author":"Srivanitchapoom","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib58","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/mds.21730","article-title":"Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease","volume":"22","author":"Thomsen","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib59","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mds.10276","article-title":"Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study","volume":"17","author":"Hyson","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.0b013e3181d8c1b7","article-title":"Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial","volume":"74","author":"Arbouw","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib61","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib64","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1212\/WNL.42.4.726","article-title":"Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology","volume":"42","author":"Edwards","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib65","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/WNL.0b013e3181d55f24","article-title":"Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"74","author":"Zesiewicz","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib66","unstructured":"Okun M. Parkinson\u2019s treatment tips for constipation. 2011. Available at: http:\/\/movementdisorders.ufhealth.org\/2011\/09\/12\/parkinsons-treatment-tips-for-constipation. Accessed November 26, 2015."},{"key":"10.1016\/j.mcna.2016.03.002_bib67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jnnp-2012-303135","article-title":"Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology","volume":"84","author":"Asahina","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2016.03.002_bib68","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2016.03.002_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0002-9343(02)01025-2","article-title":"Water drinking as a treatment for orthostatic syndromes","volume":"112","author":"Shannon","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2016.03.002_bib70","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/jnnp.2004.038471","article-title":"The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure","volume":"75","author":"Young","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2016.03.002_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(99)02132-7","article-title":"Haemodynamic analysis of efficacy of compression hosiery in elderly fallers with orthostatic hypotension","volume":"354","author":"Henry","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.002_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/hrt.76.6.507","article-title":"Fludrocortisone in the treatment of hypotensive disorders in the elderly","volume":"76","author":"Hussain","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.mcna.2016.03.002_bib73","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.002_bib74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pcad.2012.11.004","article-title":"Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension","volume":"55","author":"Raj","year":"2013","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.mcna.2016.03.002_bib75","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1586\/14779072.2015.1057504","article-title":"Droxidopa in neurogenic orthostatic hypotension","volume":"13","author":"Kaufmann","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.mcna.2016.03.002_bib76","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.parkreldis.2015.08.023","article-title":"A\u00a0randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease","volume":"21","author":"Zhao","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib78","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A\u00a012-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib79","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","article-title":"Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2016.03.002_bib80","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/s100720200084","article-title":"Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease","volume":"23","author":"Morgante","year":"2002","journal-title":"Neurol Sci"},{"key":"10.1016\/j.mcna.2016.03.002_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.10620","article-title":"Quetiapine improves psychotic symptoms and cognition in Parkinson's disease","volume":"19","author":"Juncos","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib82","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","article-title":"Range of neuropsychiatric disturbances in patients with Parkinson's disease","volume":"67","author":"Aarsland","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2016.03.002_bib83","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib84","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0b013e31822e560e","article-title":"Associated factors for REM sleep behavior disorder in Parkinson disease","volume":"77","author":"Sixel-D\u00f6ring","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib85","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ncl.2005.06.002","article-title":"Rapid eye movement sleep parasomnias","volume":"23","author":"Schenck","year":"2005","journal-title":"Neurol Clin"},{"key":"10.1016\/j.mcna.2016.03.002_bib86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2869.2010.00848.x","article-title":"A\u00a0two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder","volume":"19","author":"Kunz","year":"2010","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.mcna.2016.03.002_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","article-title":"Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients","volume":"4","author":"Boeve","year":"2003","journal-title":"Sleep Med"},{"issue":"Pt 2","key":"10.1016\/j.mcna.2016.03.002_bib88","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/123.2.331","article-title":"Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases","volume":"123","author":"Olson","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.mcna.2016.03.002_bib89","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ncl.2009.04.003","article-title":"Tremor: clinical features, pathophysiology, and treatment","volume":"27","author":"Elble","year":"2009","journal-title":"Neurol Clin"},{"issue":"5","key":"10.1016\/j.mcna.2016.03.002_bib90","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mds.22838","article-title":"How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor","volume":"25","author":"Louis","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib91","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/123.8.1568","article-title":"Essential tremor and cerebellar dysfunction. Clinical and kinematic analysis of intention tremor","volume":"123","author":"Deuschl","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.mcna.2016.03.002_bib92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.410340115","article-title":"A\u00a0positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections","volume":"34","author":"Jenkins","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib93","series-title":"Principles and practice of movement disorders","author":"Fahn","year":"2011"},{"key":"10.1016\/j.mcna.2016.03.002_bib94","series-title":"Inderal (propranolol hydrochloride) tablets prescribing information","author":"Ayerst Laboratories Inc","year":"2002"},{"issue":"8","key":"10.1016\/j.mcna.2016.03.002_bib95","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jnnp.46.8.710","article-title":"Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol","volume":"46","author":"Leigh","year":"1983","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.002_bib96","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archneur.1986.00520010038018","article-title":"Dose-response relationship of propranolol in the treatment of essential tremor","volume":"43","author":"Koller","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib97","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4137\/JCNSD.S6561","article-title":"Pharmacotherapy of essential tremor","volume":"5","author":"Hedera","year":"2013","journal-title":"J\u00a0Cent Nerv Syst Dis"},{"issue":"10","key":"10.1016\/j.mcna.2016.03.002_bib98","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1212\/WNL.35.10.1494","article-title":"Time course of a single oral dose of propranolol in essential tremor","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.002_bib99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archneur.1972.00490130036005","article-title":"Phenylethylmalonamide (PEMA). An important metabolite of primidone","volume":"27","author":"Baumel","year":"1972","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib100","unstructured":"Mysoline (primidone, USP) [packageinsert]. Aliso Viejo (CA): Valeant Pharmaceuticals NA; 2009. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/009170s036lbl.pdf."},{"key":"10.1016\/j.mcna.2016.03.002_bib101","series-title":"Primidone","article-title":"AHFS drug information 2007","year":"2008"},{"issue":"12","key":"10.1016\/j.mcna.2016.03.002_bib102","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000163769.28552.CD","article-title":"Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"64","author":"Zesiewicz","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib103","series-title":"Neurontin (gabapentin) capsules prescribing information","author":"Parke-Davis","year":"2005"},{"issue":"9","key":"10.1016\/j.mcna.2016.03.002_bib104","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.mcna.2016.03.002_bib105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0","article-title":"Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial","volume":"15","author":"Ondo","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib106","series-title":"Topamax (topiramate) tablets and capsules prescribing information","author":"Ortho-McNeil","year":"2004"},{"issue":"2","key":"10.1016\/j.mcna.2016.03.002_bib107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/WNF.0b013e3180d09969","article-title":"Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials","volume":"31","author":"Connor","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl\u00a01","key":"10.1016\/j.mcna.2016.03.002_bib108","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1528-1157.1997.tb04512.x","article-title":"Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs","volume":"38","author":"Johannessen","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 9","key":"10.1016\/j.mcna.2016.03.002_bib109","first-page":"S448","article-title":"Multi-center, double-blind, placebo-controlled trial of topiramate in essential tremor","volume":"19","author":"Jankovic","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","article-title":"Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo","volume":"16","author":"Walters","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.mcna.2016.03.002_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-9-73","article-title":"Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study","volume":"9","author":"Scholz","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.mcna.2016.03.002_bib112","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/mds.20226","article-title":"Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease?","volume":"19","author":"Linke","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib113","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13311-013-0247-9","article-title":"Treatment of restless leg syndrome","volume":"11","author":"Comella","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.mcna.2016.03.002_bib114","unstructured":"American Academy of Neurology. https:\/\/www.aan.com."},{"issue":"5","key":"10.1016\/j.mcna.2016.03.002_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007834.pub2","article-title":"Iron for restless legs syndrome","author":"Trotti","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.mcna.2016.03.002_bib116","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(06)70576-2","article-title":"Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome","volume":"5","author":"Paulus","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib117","unstructured":"Available at: Rxlist.com."},{"key":"10.1016\/j.mcna.2016.03.002_bib118","series-title":"Parcopa (carbidopa-levodopa) orally disintegrating tablets prescribing information","author":"Azur Pharma","year":"2009"},{"key":"10.1016\/j.mcna.2016.03.002_bib119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.002_bib120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1469-8749.1972.tb02549.x","article-title":"A\u00a0new anticonvulsant in the management of minor motor seizures","volume":"14","author":"Hanson","year":"1972","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.mcna.2016.03.002_bib121","series-title":"Klonopin (clonazepam) tablets prescribing information","author":"Roche Laboratories Inc","year":"1997"},{"key":"10.1016\/j.mcna.2016.03.002_bib122","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0014-2999(98)00896-6","article-title":"Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 receptors","volume":"366","author":"Perachon","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mcna.2016.03.002_bib123","series-title":"Requip (ropinirole hydrochloride) tablets prescribing information","author":"GlaxoSmithKline","year":"2005"},{"key":"10.1016\/j.mcna.2016.03.002_bib124","series-title":"Mirapex (pramipexole dihydrochloride) tablets prescribing information","author":"Boehringer Ingelheim","year":"2011"},{"key":"10.1016\/j.mcna.2016.03.002_bib125","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.57.9.1717","article-title":"Treatment of idiopathic restless legs syndrome (RLS) with gabapentin","volume":"57","author":"Happe","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2016.03.002_bib126","series-title":"Lyrica(pregabalin) capsules prescribing information","author":"Pfizer, Inc","year":"2007"},{"issue":"2","key":"10.1016\/j.mcna.2016.03.002_bib127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.mcna.2016.03.002_bib128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","article-title":"The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group","volume":"14","author":"Garcia-Borreguero","year":"2013","journal-title":"Sleep Med"},{"key":"10.1016\/j.mcna.2016.03.002_bib129","series-title":"Tegretol (carbamazepine) chewable tablets, tablets, and suspension and Tegretol XR (carbamazepine) extended-release tablets prescribing information","author":"Novartis Pharmaceuticals","year":"2003"},{"issue":"6415","key":"10.1016\/j.mcna.2016.03.002_bib130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/bmj.288.6415.444","article-title":"Treatment of the restless legs syndrome with carbamazepine: a double blind study","volume":"288","author":"Telstad","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.mcna.2016.03.002_bib131","series-title":"Public health advisory: Information for healthcare professionals: carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics)","author":"US Food and Drug Administration","year":"2007"},{"issue":"3","key":"10.1016\/j.mcna.2016.03.002_bib132","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1476-5381.1996.tb15707.x","article-title":"alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception","volume":"119","author":"Sierralta","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mcna.2016.03.002_bib133","series-title":"Catapres-TTS (clonidine) Transdermal Therapeutic System prescribing information","author":"Boehringer Ingelheim Pharmaceuticals, Inc","year":"2004"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.002_bib134","first-page":"52","article-title":"Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome","volume":"19","author":"Wagner","year":"1996","journal-title":"Sleep"},{"key":"10.1016\/j.mcna.2016.03.002_bib135","series-title":"Symmetrel (amantadine hydrochloride) tablets and syrup prescribing information","author":"Endo Laboratories","year":"2009"},{"key":"10.1016\/j.mcna.2016.03.002_bib136","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/1531-8257(200003)15:2<324::AID-MDS1020>3.0.CO;2-4","article-title":"Amantadine is beneficial in restless legs syndrome","volume":"15","author":"Evidente","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.mcna.2016.03.002_bib137","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jmwh.2009.01.003","article-title":"Leg cramps and restless legs syndrome during pregnancy","volume":"54","author":"Hensley","year":"2009","journal-title":"J\u00a0Midwifery Womens Health"},{"key":"10.1016\/j.mcna.2016.03.002_bib138","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.sleep.2004.01.014","article-title":"Restless legs syndrome in end-stage renal disease","volume":"5","author":"Gigli","year":"2004","journal-title":"Sleep Med"},{"issue":"6","key":"10.1016\/j.mcna.2016.03.002_bib139","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/sleep\/26.6.717","article-title":"Change in periodic limb movement index during treatment of obstructive sleep apnea with continuous positive airway pressure","volume":"26","author":"Baran","year":"2003","journal-title":"Sleep"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T21:20:54Z","timestamp":1748899254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712516000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":139,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0025712516000328"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2016.03.002","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Movement Disorders","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}